Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Margaret Ann Shipp, M.D.

TitleProfessor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
Mayer 513
44 Binney St
Boston MA 02115
Phone617/632-3874
Fax617/632-4734

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA. BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8. Mol Cell Biol. 2013 Feb; 33(4):845-57.
    View in: PubMed
  2. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013 Jan 1; 73(1):86-96.
    View in: PubMed
  3. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, Danial NN. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012 Oct 16; 22(4):547-60.
    View in: PubMed
  4. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, Croci MC, Shipp MA, Mesri EA, Albini A, Rabinovich GA. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med. 2012 Oct 22; 209(11):1985-2000.
    View in: PubMed
  5. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Habermann TM, Getz G, Kung AL, Golub TR, Shipp MA. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72.
    View in: PubMed
  6. Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012; 7(4):e33813.
    View in: PubMed
  7. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernández-Lemus E, Schwarz-Cruz y Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar 6; 109(10):3879-84.
    View in: PubMed
  8. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012 Mar 15; 18(6):1611-8.
    View in: PubMed
  9. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012 Jan 5; 481(7379):90-3.
    View in: PubMed
  10. Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA, Kutok JL, Drapkin RI, Rodig SJ. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol. 2011 Oct; 35(10):1531-9.
    View in: PubMed
  11. Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 2011 Apr 21; 117(16):4315-22.
    View in: PubMed
  12. Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A. 2011 Feb 15; 108(7):2873-8.
    View in: PubMed
  13. Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica. 2010 Dec; 95(12):2056-62.
    View in: PubMed
  14. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Oct 28; 116(17):3268-77.
    View in: PubMed
  15. Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res. 2010 Apr 1; 16(7):2122-30.
    View in: PubMed
  16. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1; 115(13):2578-85.
    View in: PubMed
  17. Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood. 2009 Dec 17; 114(26):5315-21.
    View in: PubMed
  18. Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA. BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Mol Cell. 2009 Oct 9; 36(1):110-20.
    View in: PubMed
  19. Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL. No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma. Diagn Mol Pathol. 2009 Sep; 18(3):144-9.
    View in: PubMed
  20. Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R. GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis. J Biol Chem. 2009 Apr 24; 284(17):11385-95.
    View in: PubMed
  21. Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, Takeyama K, Shipp MA. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol. 2009 Feb; 144(3):358-66.
    View in: PubMed
  22. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008 Jun 1; 14(11):3338-44.
    View in: PubMed
  23. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008 Feb 15; 111(4):2230-7.
    View in: PubMed
  24. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007 Aug 7; 104(32):13134-9.
    View in: PubMed
  25. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007 Aug; 12(2):171-85.
    View in: PubMed
  26. Takeyama K, Monti S, Manis JP, Dal Cin P, Getz G, Beroukhim R, Dutt S, Aster JC, Alt FW, Golub TR, Shipp MA. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene. 2008 Jan 10; 27(3):318-22.
    View in: PubMed
  27. Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 2007 Sep 15; 110(6):2067-74.
    View in: PubMed
  28. Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP. High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma. 2007 May; 48(5):870-80.
    View in: PubMed
  29. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007 May 1; 25(13):1741-6.
    View in: PubMed
  30. Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2007 Feb 27; 104(9):3207-12.
    View in: PubMed
  31. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007 Jan; 31(1):106-12.
    View in: PubMed
  32. Shipp MA. Molecular signatures define new rational treatment targets in large B-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2007; 265-9.
    View in: PubMed
  33. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006 Dec 1; 12(23):7174-9.
    View in: PubMed
  34. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006 Nov 15; 108(10):3428-33.
    View in: PubMed
  35. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA. BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol. 2006 Jul; 26(14):5348-59.
    View in: PubMed
  36. Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC, Shipp MA. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 1):3265-71.
    View in: PubMed
  37. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006 Feb 20; 203(2):311-7.
    View in: PubMed
  38. Shipp M. New concepts in treatment approaches and prognostic factors in aggressive NHL. Clin Adv Hematol Oncol. 2006 Feb; 4(2):107-9.
    View in: PubMed
  39. Takahashi H, Feuerhake F, Monti S, Kutok JL, Aster JC, Shipp MA. Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma. Blood. 2006 Jan 15; 107(2):844-5.
    View in: PubMed
  40. Aguiar RC, Takeyama K, He C, Kreinbrink K, Shipp MA. B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J Biol Chem. 2005 Oct 7; 280(40):33756-65.
    View in: PubMed
  41. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15; 106(4):1392-9.
    View in: PubMed
  42. Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2005 May 1; 11(9):3417-24.
    View in: PubMed
  43. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005 Aug 15; 106(4):1164-74.
    View in: PubMed
  44. Shipp MA, Aquino SL, Harris NL. Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass. N Engl J Med. 2005 Apr 21; 352(16):1697-704.
    View in: PubMed
  45. Rodig SJ, Savage KJ, Nguyen V, Pinkus GS, Shipp MA, Aster JC, Kutok JL. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol. 2005 Feb; 29(2):196-203.
    View in: PubMed
  46. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005 Mar 1; 105(5):1851-61.
    View in: PubMed
  47. Louis K, Guérineau N, Fromigué O, Defamie V, Collazos A, Anglard P, Shipp MA, Auberger P, Joubert D, Mari B. Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoforms. J Biol Chem. 2005 Jan 14; 280(2):1272-83.
    View in: PubMed
  48. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005 Jan 1; 105(1):308-16.
    View in: PubMed
  49. Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004 Apr; 45(4):761-7.
    View in: PubMed
  50. Fromigué O, Louis K, Wu E, Belhacène N, Loubat A, Shipp M, Auberger P, Mari B. Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. Int J Cancer. 2003 Sep 1; 106(3):355-63.
    View in: PubMed
  51. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 1; 102(12):3871-9.
    View in: PubMed
  52. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003 Dec 1; 102(12):4187-90.
    View in: PubMed
  53. Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC, Shipp MA. The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem. 2003 Jun 13; 278(24):21930-7.
    View in: PubMed
  54. Braziel RM, Shipp MA, Feldman AL, Espina V, Winters M, Jaffe ES, Petricoin EF, Liotta LA. Molecular diagnostics. Hematology Am Soc Hematol Educ Program. 2003; 279-93.
    View in: PubMed
  55. Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma. 2002 Apr; 43(4):793-7.
    View in: PubMed
  56. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002 Mar 1; 20(5):1288-94.
    View in: PubMed
  57. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002 Jan; 8(1):68-74.
    View in: PubMed
  58. de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001 Oct; 25(10):1277-82.
    View in: PubMed
  59. Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J Cell Biochem. 2001; 82(4):549-55.
    View in: PubMed
  60. Loeffler M, Shipp M, Stein H. 2. Report on the workshop: "Clinical consequences of pathology and prognostic factors in aggressive NHL". Ann Hematol. 2001; 80 Suppl 3:B8-12.
    View in: PubMed
  61. Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol. 2000 Dec 22; 170(1-2):131-42.
    View in: PubMed
  62. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood. 2000 Dec 15; 96(13):4328-34.
    View in: PubMed
  63. Anderson IC, Mari SE, Broderick RJ, Mari BP, Shipp MA. The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res. 2000 Jan 15; 60(2):269-72.
    View in: PubMed
  64. Aguiar RC, Yakushijin Y, Kharbanda S, Tiwari S, Freeman GJ, Shipp MA. PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood. 1999 Oct 1; 94(7):2403-13.
    View in: PubMed
  65. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr; 17(4):1244.
    View in: PubMed
  66. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol. 1999 Jan; 10(1):13-9.
    View in: PubMed
  67. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol. 1999 Jan; 17(1):423-9.
    View in: PubMed
  68. Howard OM, Shipp MA. The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas. Curr Opin Oncol. 1998 Sep; 10(5):385-91.
    View in: PubMed
  69. Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W, Anderson I, Shipp MA. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. Blood. 1998 Jun 1; 91(11):4282-91.
    View in: PubMed
  70. Mari BP, Anderson IC, Mari SE, Ning Y, Lutz Y, Kobzik L, Shipp MA. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem. 1998 Jan 2; 273(1):618-26.
    View in: PubMed
  71. Ishimaru F, Mari B, Shipp MA. The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood. 1997 Jun 1; 89(11):4136-45.
    View in: PubMed
  72. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol. 1997 Apr; 15(4):1631-7.
    View in: PubMed
  73. Shipp MA. Can we improve upon the International Index? Ann Oncol. 1997; 8 Suppl 1:43-7.
    View in: PubMed
  74. Ganju RK, Shpektor RG, Brenner DG, Shipp MA. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood. 1996 Dec 1; 88(11):4159-65.
    View in: PubMed
  75. Ishimaru F, Potter NS, Shipp MA. Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias. Exp Hematol. 1996 Jan; 24(1):43-8.
    View in: PubMed
  76. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995 Dec; 13(12):2916-23.
    View in: PubMed
  77. Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res. 1995 Sep 15; 55(18):4120-6.
    View in: PubMed
  78. Drazen JM, Evans JF, Stevens RL, Shipp MA. Inflammatory effector mechanisms in asthma. Am J Respir Crit Care Med. 1995 Jul; 152(1):403-7.
    View in: PubMed
  79. Ishimaru F, Shipp MA. Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood. 1995 Jun 1; 85(11):3199-207.
    View in: PubMed
  80. Ganju RK, Sunday M, Tsarwhas DG, Card A, Shipp MA. CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. J Clin Invest. 1994 Nov; 94(5):1784-91.
    View in: PubMed
  81. Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994 May; 5(5):397-400.
    View in: PubMed
  82. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994 Mar 1; 83(5):1165-73.
    View in: PubMed
  83. Salles G, Shipp MA, Coiffier B. Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin Hematol. 1994 Jan; 31(1):46-69.
    View in: PubMed
  84. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood. 1993 Dec 15; 82(12):3539-47.
    View in: PubMed
  85. Salles G, Rodewald HR, Chin BS, Reinherz EL, Shipp MA. Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo. Proc Natl Acad Sci U S A. 1993 Aug 15; 90(16):7618-22.
    View in: PubMed
  86. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood. 1993 Aug 15; 82(4):1052-70.
    View in: PubMed
  87. Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, Tung N, Wheeler C, Beard CJ, Canellos GP, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993 Jul; 11(7):1336-43.
    View in: PubMed
  88. King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest. 1993 May; 91(5):1969-73.
    View in: PubMed
  89. Heagy W, Shipp MA, Finberg RW. Opioid receptor agonists and Ca2+ modulation in human B cell lines. J Immunol. 1992 Dec 15; 149(12):4074-81.
    View in: PubMed
  90. Sunday ME, Hua J, Torday JS, Reyes B, Shipp MA. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest. 1992 Dec; 90(6):2517-25.
    View in: PubMed
  91. Salles G, Chen CY, Reinherz EL, Shipp MA. CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. Blood. 1992 Oct 15; 80(8):2021-9.
    View in: PubMed
  92. Shipp M. Prognostic factors in non-Hodgkin's lymphoma. Curr Opin Oncol. 1992 Oct; 4(5):856-62.
    View in: PubMed
  93. Chen CY, Salles G, Seldin MF, Kister AE, Reinherz EL, Shipp MA. Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site. J Immunol. 1992 May 1; 148(9):2817-25.
    View in: PubMed
  94. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A. 1991 Dec 1; 88(23):10662-6.
    View in: PubMed
  95. Shipp MA, Stefano GB, Switzer SN, Griffin JD, Reinherz EL. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood. 1991 Oct 1; 78(7):1834-41.
    View in: PubMed
  96. Shapiro CL, Yeap BY, Godleski J, Jochelson MS, Shipp MA, Skarin AT, Canellos GP. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer. 1991 Aug 15; 68(4):699-705.
    View in: PubMed
  97. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991 Jul; 9(7):1196-203.
    View in: PubMed
  98. Stefano GB, Shipp MA, Scharrer B. A possible immunoregulatory function for [Met]-enkephalin-Arg6-Phe7 involving human and invertebrate granulocytes. J Neuroimmunol. 1991 Feb; 31(2):97-103.
    View in: PubMed
  99. Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, Canellos GP. Report of the first workshop on prognostic factors in large-cell lymphomas. Ann Oncol. 1991 Feb; 2 Suppl 2:213-7.
    View in: PubMed
  100. Shipp MA, Stefano GB, D'Adamio L, Switzer SN, Howard FD, Sinisterra J, Scharrer B, Reinherz EL. Downregulation of enkephalin-mediated inflammatory responses by CD10/neutral endopeptidase 24.11. Nature. 1990 Sep 27; 347(6291):394-6.
    View in: PubMed
  101. Hughes TK, Smith EM, Chin R, Cadet P, Sinisterra J, Leung MK, Shipp MA, Scharrer B, Stefano GB. Interaction of immunoactive monokines (interleukin 1 and tumor necrosis factor) in the bivalve mollusc Mytilus edulis. Proc Natl Acad Sci U S A. 1990 Jun; 87(12):4426-9.
    View in: PubMed
  102. Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, Rosenthal DS, Skarin AT, Canellos GP. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol. 1990 Jan; 8(1):84-93.
    View in: PubMed
  103. D'Adamio L, Shipp MA, Masteller EL, Reinherz EL. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc Natl Acad Sci U S A. 1989 Sep; 86(18):7103-7.
    View in: PubMed
  104. Shipp MA, Klatt MM, Yeap B, Jochelson MS, Mauch PM, Rosenthal DS, Skarin AT, Canellos GP. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol. 1989 May; 7(5):613-8.
    View in: PubMed
  105. Barker PE, Shipp MA, D'Adamio L, Masteller EL, Reinherz EL. The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27). J Immunol. 1989 Jan 1; 142(1):283-7.
    View in: PubMed
  106. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A. 1989 Jan; 86(1):297-301.
    View in: PubMed
  107. Ernst TJ, Gazdar A, Ritz J, Shipp MA. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood. 1988 Oct; 72(4):1163-7.
    View in: PubMed
  108. Shipp MA, Richardson NE, Sayre PH, Brown NR, Masteller EL, Clayton LK, Ritz J, Reinherz EL. Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4819-23.
    View in: PubMed
  109. Tantravahi R, Shipp MA, Greeley TA, Pavelka K, Bern MM, Rosenthal DS, Frei E. Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11) Cancer Genet Cytogenet. 1988 Jan; 30(1):83-90.
    View in: PubMed
  110. Shipp MA, Reinherz EL. Differential expression of nuclear proto-oncogenes in T cells triggered with mitogenic and nonmitogenic T3 and T11 activation signals. J Immunol. 1987 Oct 1; 139(7):2143-8.
    View in: PubMed
  111. Canellos GP, Skarin AT, Klatt MM, Rosenthal DS, Case DC, Pinkus GS, Jochelson MS, Yeap BY, Shipp MA. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol. 1987 Apr; 24(2 Suppl 1):2-7.
    View in: PubMed
  112. Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, Rosenthal DS, Skarin AT, Canellos GP. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun; 104(6):757-65.
    View in: PubMed
  113. Douglass EC, Green AA, Wrenn E, Champion J, Shipp M, Pratt CB. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol. 1985; 13(4):187-90.
    View in: PubMed
  114. Shipp MA, Takvorian RC, Canellos GP. High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma. Am J Med. 1984 Nov; 77(5):845-50.
    View in: PubMed
  115. Shipp MA, Schwartz BD, Kannapell CC, Griffith RC, Scott MG, Ahmed P, Davie JM, Nahm MH. A unique DR-related B cell differentiation antigen. J Immunol. 1983 Nov; 131(5):2458-67.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Shipp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (572) concept(s)
_
Co-Authors
See all (74) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_